Statement: Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.
Primary_evidence: Outcome Measurement:    Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment   The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.   Since there is no independent reviewer, only the investigator response was reported.   Time frame: up to week 12 Results 1:    Arm/Group Title: Lapatinib + Bevacizumab   Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)   Overall Number of Participants Analyzed: 52   Measure Type: Count of Participants   Unit of Measure: Participants  No disease progression by Week 12: 36  69.2%   Disease progression or death by Week 12: 16  30.8%